Abstract
Thrombospondin (TSP)-1 and -2 are potent inhibitors of angiogenesis in vivo and of microvascular endothelial cell responses to angiogenic factors in vitro. The anti-angiogenic activity of thrombospondins is contained in a structural domain known as the TSP type I repeat or TSR. TSR domains are present in many other proteins, several of which have also been shown to have anti-angiogenic activity and a peptide-mimetic drug based on the domain is in clinical trials as an anti-angiogenic anti-cancer therapy. We have identified CD36 as the endothelial cell receptor for TSP-1 and -2 and showed that it is necessary for their anti-angiogenic activity. CD36-mediated antiangiogenic activity in endothelial cells is due to its ability to activate a specific signaling cascade that results in diversion of a proangiogenic response to an apoptotic response. Recently we identified a circulating protein, histidine-rich glycoprotein (HRGP), that contains a CD36 homology domain and that acts as a soluble decoy to block the anti-angiogenic activities of TSPs, thereby promoting angiogenesis. The tripartite interactions among CD36, TSR domains and HRGP in tissues may play an important role in regulating physiological and pathological angiogenesis.
Keywords: Angiogenesis, CD36, TSP-1, TSP-2, HRGP, endothelial cells
Current Pharmaceutical Design
Title: CD36-TSP-HRGP Interactions in the Regulation of Angiogenesis
Volume: 13 Issue: 35
Author(s): Roy L. Silverstein and Maria Febbraio
Affiliation:
Keywords: Angiogenesis, CD36, TSP-1, TSP-2, HRGP, endothelial cells
Abstract: Thrombospondin (TSP)-1 and -2 are potent inhibitors of angiogenesis in vivo and of microvascular endothelial cell responses to angiogenic factors in vitro. The anti-angiogenic activity of thrombospondins is contained in a structural domain known as the TSP type I repeat or TSR. TSR domains are present in many other proteins, several of which have also been shown to have anti-angiogenic activity and a peptide-mimetic drug based on the domain is in clinical trials as an anti-angiogenic anti-cancer therapy. We have identified CD36 as the endothelial cell receptor for TSP-1 and -2 and showed that it is necessary for their anti-angiogenic activity. CD36-mediated antiangiogenic activity in endothelial cells is due to its ability to activate a specific signaling cascade that results in diversion of a proangiogenic response to an apoptotic response. Recently we identified a circulating protein, histidine-rich glycoprotein (HRGP), that contains a CD36 homology domain and that acts as a soluble decoy to block the anti-angiogenic activities of TSPs, thereby promoting angiogenesis. The tripartite interactions among CD36, TSR domains and HRGP in tissues may play an important role in regulating physiological and pathological angiogenesis.
Export Options
About this article
Cite this article as:
Silverstein L. Roy and Febbraio Maria, CD36-TSP-HRGP Interactions in the Regulation of Angiogenesis, Current Pharmaceutical Design 2007; 13 (35) . https://dx.doi.org/10.2174/138161207782794185
DOI https://dx.doi.org/10.2174/138161207782794185 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Magnetic Nanoparticles in Brain Disease Diagnosis and Targeting Drug Delivery
Current Nanoscience PET Imaging to Monitor Cancer Therapy
Current Pharmaceutical Biotechnology Nanomedicines Based Drug Delivery Systems for Anti-Cancer Targeting and Treatment
Current Drug Delivery Small Heat Shock Proteins (sHSPs) As Potential Drug Targets
Current Pharmaceutical Biotechnology Clinical Development of MET Targeted Therapy For Human Cancer
Current Cancer Therapy Reviews Pharmacology of Sigma (σ) Receptor Ligands from a Behavioral Perspective
Current Pharmaceutical Design Impact of Hybrid-polar Histone Deacetylase Inhibitor m-Carboxycinnamic Acid bis-Hydroxyamide on Human Pancreatic Adenocarcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Schiff Bases and their Metal Complexes as Potential Anticancer Candidates: A Review of Recent Works
Anti-Cancer Agents in Medicinal Chemistry Cannabinoid Drugs and Enhancement of Endocannabinoid Responses: Strategies for a Wide Array of Disease States
Current Molecular Medicine Human Microdialysis
Current Pharmaceutical Biotechnology Schiff Bases and Complexes: A Review on Anti-Cancer Activity
Anti-Cancer Agents in Medicinal Chemistry miRNAs as Modulators of Cholesterol in Breast Cancer Stem Cells: An Approach to Overcome Drug Resistance in Cancer
Current Drug Targets Recent Advances in Luminescent Carbon Dots
Current Analytical Chemistry Investigation on the Interaction Between Anthracyclines and DNA in the Presence of Quercetin by Resonance Light Scattering Technique and Its Analytical Application
Current Analytical Chemistry Editorial from Guest Editor (DNA Methylation: A Target for Current and Future Therapies?)
Epigenetic Diagnosis & Therapy (Discontinued) Advances in the Management of Brain Tumors in Infants
Current Cancer Therapy Reviews Recent Advances in Pretargeted Radioimmunotherapy
Current Medicinal Chemistry Nitrone Derivatives as Therapeutics: From Chemical Modification to Specific-targeting
Current Topics in Medicinal Chemistry Mitochondria in Cancer Stem Cells: A Target for Therapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Cancer Stem Cells and the Biology of Brain Tumors
Current Stem Cell Research & Therapy